$3.54
8.92% today
Nasdaq, Apr 02, 10:17 pm CET
ISIN
US4622601007
Symbol
IOVA
Sector
Industry

Iovance Biotherapeutics Inc Stock price

$3.25
-0.79 19.55% 1M
-6.10 65.24% 6M
-4.15 56.08% YTD
-10.94 77.10% 1Y
-13.86 81.01% 3Y
-24.69 88.37% 5Y
-9.30 74.10% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.08 2.40%
ISIN
US4622601007
Symbol
IOVA
Sector
Industry

Key metrics

Market capitalization $1.07b
Enterprise Value $800.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.88
P/S ratio (TTM) P/S ratio 6.49
P/B ratio (TTM) P/B ratio 1.40
Revenue growth (TTM) Revenue growth 13,698.99%
Revenue (TTM) Revenue $164.07m
EBIT (operating result TTM) EBIT $-395.28m
Free Cash Flow (TTM) Free Cash Flow $-364.05m
Cash position $323.78m
EPS (TTM) EPS $-1.30
P/E forward negative
P/S forward 2.35
EV/Sales forward 1.77
Short interest 22.52%
Show more

Is Iovance Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Iovance Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Iovance Biotherapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Iovance Biotherapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Iovance Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
164 164
13,687% 13,687%
100%
- Direct Costs 146 146
286% 286%
89%
18 18
148% 148%
11%
- Selling and Administrative Expenses 87 87
87% 87%
53%
- Research and Development Expense 282 282
18% 18%
172%
-352 -352
18% 18%
-214%
- Depreciation and Amortization 44 44
32% 32%
27%
EBIT (Operating Income) EBIT -395 -395
14% 14%
-241%
Net Profit -372 -372
16% 16%
-227%

In millions USD.

Don't miss a Thing! We will send you all news about Iovance Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Iovance Biotherapeutics Inc Stock News

Positive
The Motley Fool
11 days ago
Iovance Biotherapeutics (IOVA -0.28%) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval of a key therapy -- its shares have significantly lagged the market.
Positive
The Motley Fool
11 days ago
Most investors know the market's down quite a bit from February's high. Not all investors realize that a handful of compelling stocks were already sliding before the marketwide correction started, and that several of these same names haven't yet even hinted at a recovery.
Neutral
GlobeNewsWire
12 days ago
SAN CARLOS, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on March 20, 2025 (the “Date of Grant”), the Company approved the grant of induce...
More Iovance Biotherapeutics Inc News

Company Profile

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Head office United States
CEO Frederick Vogt
Employees 838
Founded 2007
Website www.iovance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today